AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2744908 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric dosing with sustained-release theophylline (450 mg b.i.d.)
Number of subjects: 10
Study 2744908 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dosing with sustained-release theophylline (270 mg plus 630 mg)
Number of subjects: 10
Study 2744908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 791605 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg propranolol
Number of subjects: 8
Study 791605 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 8
Study 791605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31831564 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg oral) with Gemcitabine (1,000 mg/m2 i.v.) and Nab-Paclitaxel (125 mg/m2 i.v.)
Number of subjects: 9
Study 31831564 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor-GEM-nab-paclitaxel combination
Number of subjects: 9
Study 31831564 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 9
Study 30755255 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (10-50 mg daily)
Number of subjects: 457
Study 30755255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 28320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid provided
Number of subjects: 20
Study 28320312 — intervention group
Group type: COMPARATOR
Intervention: No cognitive aid
Number of subjects: 20
Study 23455386 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy-guided suprascapular nerve block using 10 mL 0.5 % ropivacaine with 1:200,000 epinephrine
Number of subjects: 30
Study 23455386 — intervention group
Group type: COMPARATOR
Intervention: Placebo using 10 mL 0.9 % saline
Number of subjects: 30
Study 23018151 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid with or without clopidogrel
Number of subjects: 4670
Study 21725239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 152
Study 21725239 — intervention group
Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 152
Study 21725239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg) and Control
Number of subjects: 152
Study 19386610 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 20
Study 19386610 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 20
Study 16469019 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg CR oxybutynin
Number of subjects: 237
Study 16469019 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg CR oxybutynin
Number of subjects: 237
Study 16469019 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg CR oxybutynin
Number of subjects: 237
Study 15117983 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF given every 3 weeks for 12 courses
Number of subjects: 0
Study 15117983 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF-->DOX (four courses of full-dose DOX followed by eight courses of i.v. CMF)
Number of subjects: 0
Study 15117983 — intervention group
Group type: COMPARATOR
Intervention: CMF/DOX (alternating two courses of CMF with one course of DOX for a total of 12 courses)
Number of subjects: 0
Study 11694099 — intervention group
Group type: EXPERIMENTAL
Intervention: In-the-ear (ITE) hearing aid
Number of subjects: 29
Study 11694099 — intervention group
Group type: EXPERIMENTAL
Intervention: Behind-the-ear (BTE) hearing aid
Number of subjects: 29
Study 9429741 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (MK-0476), 10 mg d-1 for 7 days
Number of subjects: 24
Study 9429741 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (MK-0476), 7 mg intravenous (5 min infusion)
Number of subjects: 24
Study 9429741 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (MK-0476), 10 mg oral dose
Number of subjects: 24
Study 8381624 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 10 mg
Number of subjects: 12
Study 8381624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NED) 10 mg
Number of subjects: 12
Study 8381624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 12
Study 3690977 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory loading only
Number of subjects: 18
Study 3690977 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory plus expiratory loading
Number of subjects: 18
Study 3690977 — intervention group
Group type: COMPARATOR
Intervention: No loading
Number of subjects: 18
Study 30509399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3G and 4G rapid screening tests or self-tests
Number of subjects: 512
Study 30509399 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G test
Number of subjects: 512
Study 30509399 — intervention group
Group type: COMPARATOR
Intervention: 3G test (sold as a 4G test on a website)
Number of subjects: 512
Study 27450091 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-flock treatment with tilmicosin and enhanced biosecurity
Number of subjects: 8146
Study 27450091 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 8146
Study 24462498 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-supported behavioral intervention
Number of subjects: 122
Study 22238418 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive patients (OEF >1.13)
Number of subjects: 43
Study 22238418 — intervention group
Group type: COMPARATOR
Intervention: PET-negative patients (OEF ≤1.13)
Number of subjects: 43
Study 22238418 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive patients with TIA as qualifying event
Number of subjects: 43
Study 22238418 — intervention group
Group type: COMPARATOR
Intervention: PET-negative patients with TIA as qualifying event
Number of subjects: 43
Study 21029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil injection (10 µg i.v. once every 12 hours for 7 days)
Number of subjects: 63
Study 21029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil injection
Number of subjects: 63
Study 21029674 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 63
Study 18294034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided access (group 1)
Number of subjects: 100
Study 18294034 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided access (group 2)
Number of subjects: 100
Study 15797147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse administered intervention
Number of subjects: 294
Study 15797147 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 294
Study 12879464 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI >= 30.0 kg/m(2))
Number of subjects: 3759
Study 12879464 — intervention group
Group type: EXPERIMENTAL
Intervention: All obese patients
Number of subjects: 3759
Study 12879464 — intervention group
Group type: COMPARATOR
Intervention: Normal weight women (BMI 21.0-24.9 kg/m(2))
Number of subjects: 3759
Study 12879464 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 3759
Study 10489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase capsules
Number of subjects: 18
Study 10489912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg sc)
Number of subjects: 18
Study 8531896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1835661 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus adriamycin plus cisplatin (EAP)
Number of subjects: 0
Study 1835661 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus 5‐fluorouracil plus leucovorin (ELF)
Number of subjects: 0
Study 1835661 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion 5‐fluorouracil plus cisplatin
Number of subjects: 0
Study 1835661 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methotrexate plus 5‐fluorouracil plus adriamycin (FAMTX)
Number of subjects: 0
Study 1835661 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil, adriamycin and mitomycin (FAM)
Number of subjects: 0
Study 1835661 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX
Number of subjects: 0
Study 7034916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide, 2 to 6 mg/d
Number of subjects: 10
Study 7034916 — intervention group
Group type: COMPARATOR
Intervention: Furosemide, 40 to 160 mg/d
Number of subjects: 10
Study 7034916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 10
Study 30965355 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐sensitivity intervention (PremieStart, n = 60)
Number of subjects: 123
Study 30965355 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 63)
Number of subjects: 123
Study 28816687 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mm diameter prosthesis
Number of subjects: 18
Study 28816687 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mm diameter prosthesis
Number of subjects: 18
Study 24876430 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Meter with in-built insulin calculator
Number of subjects: 164
Study 24876430 — intervention group
Group type: COMPARATOR
Intervention: Usual method of testing blood glucose and deciding insulin doses
Number of subjects: 164
Study 22577270 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic complex containing B. bifidum, L. acidophilus, L. casei, and L. salivarius for 8 weeks
Number of subjects: 40
Study 22577270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skim milk powder and dextrose)
Number of subjects: 40
Study 19229814 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus renal artery stenting (angioplasty group)
Number of subjects: 168
Study 19229814 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (drug therapy group)
Number of subjects: 168
Study 17312447 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 591
Study 17312447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 15064916 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-10 mg/day, once or twice daily)
Number of subjects: 55
Study 15064916 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine (5-10 mg/day, once or twice daily)
Number of subjects: 55
Study 11870677 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg tablet (test formulation)
Number of subjects: 24
Study 11870677 — intervention group
Group type: COMPARATOR
Intervention: Norvasc 5 mg tablet (reference formulation)
Number of subjects: 24
Study 9781523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 156
Study 9781523 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 156
Study 9781523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 156
Study 8170179 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty without prior thrombolytic therapy
Number of subjects: 0
Study 8170179 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate adjunctive angioplasty after thrombolytic therapy
Number of subjects: 0
Study 8170179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue angioplasty after failed thrombolytic therapy
Number of subjects: 0
Study 8170179 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred adjunctive angioplasty during the weeks after infarction
Number of subjects: 0
Study 3342656 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with InspirEase (3 puffs of metaproterenol 0.65 mg/puff) plus nebulizer with placebo
Number of subjects: 75
Study 3342656 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI with InspirEase plus nebulizer with 15 mg metaproterenol
Number of subjects: 75
Study 3342656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 2041147 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg OFLX (twice daily)
Number of subjects: 113
Study 2041147 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg OFLX (twice daily)
Number of subjects: 113
Study 2041147 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg OFLX (twice daily)
Number of subjects: 113
Study 2041147 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg OFLX (twice daily)
Number of subjects: 113
Study 1108706 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (inspired concentration, 1.24%)
Number of subjects: 12
Study 1108706 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (inspired concentration, 0.77%)
Number of subjects: 12
Study 1108706 — intervention group
Group type: COMPARATOR
Intervention: Control (awake state)
Number of subjects: 12
Study 30921105 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy intervention at Los Angeles site
Number of subjects: 541
Study 30921105 — intervention group
Group type: COMPARATOR
Intervention: Comparison group at Los Angeles site
Number of subjects: 541
Study 30921105 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy intervention at Miami site
Number of subjects: 541
Study 30921105 — intervention group
Group type: COMPARATOR
Intervention: Comparison group at Miami site
Number of subjects: 541
Study 30921105 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy intervention at both sites
Number of subjects: 541
Study 30921105 — intervention group
Group type: COMPARATOR
Intervention: Comparison group at both sites
Number of subjects: 541
Study 25989270 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus pimasertib (45 mg/day)
Number of subjects: 16
Study 25989270 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus pimasertib (60 mg/day)
Number of subjects: 16
Study 22621705 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (pranayama and meditation)
Number of subjects: 22
Study 22621705 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual rehabilitation care)
Number of subjects: 22
Study 20979462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month cessation
Number of subjects: 883
Study 20979462 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month cessation
Number of subjects: 883
Study 18809689 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of the instructor
Number of subjects: 0
Study 17306636 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic 270 degrees Toupet fundoplication
Number of subjects: 56
Study 17306636 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic 360 degrees 'floppy' Nissen fundoplication
Number of subjects: 56
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal walking (WP)
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal running (RP)
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee extension torque
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee flexion torque
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of WP with knee extension torque
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of WP with knee flexion torque
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of RP with knee extension torque
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of RP with knee flexion torque
Number of subjects: 88
Study 14985997 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal running (RP) adjusted by thigh muscle torque
Number of subjects: 88
Study 11580742 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with six monthly depot injections of leuprolide acetate (LA)
Number of subjects: 36
Study 11580742 — intervention group
Group type: COMPARATOR
Intervention: Short-term treatment with two monthly LA injections
Number of subjects: 36
Study 11580742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative blood loss
Number of subjects: 36
Study 9424883 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan and lyophilized human placenta dressing
Number of subjects: 50
Study 9424883 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 50
Study 7892970 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 72
Study 3107601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 20 mg i.v.
Number of subjects: 20
Study 3107601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 29395308 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-fibrin patch
Number of subjects: 164
Study 29395308 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 164
Study 29230375 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging with prior information about normal findings
Number of subjects: 660
Study 29230375 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging without prior information
Number of subjects: 660
Study 29230375 — intervention group
Group type: COMPARATOR
Intervention: Best practice care (quality information without imaging)
Number of subjects: 660
Study 29230375 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced reporting strategies (for imaging results)
Number of subjects: 660
Study 29230375 — intervention group
Group type: COMPARATOR
Intervention: Best practice care
Number of subjects: 660
Study 25928620 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) therapy for 24 weeks along with guideline-directed medical therapy
Number of subjects: 200
Study 25928620 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy for 24 weeks
Number of subjects: 200
Study 24066966 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P Discussion Groups and Stress Control
Number of subjects: 0
Study 24066966 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 0
Study 22112189 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 357
Study 22112189 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 357
Study 19896571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate (D‐MPH)
Number of subjects: 154
Study 19896571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 16476893 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy
Number of subjects: 209
Study 16476893 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 209
Study 16476893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 209
Study 16476893 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 209
Study 15189800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neuroendocrineimmune dysfunction syndrome (CNDS)
Number of subjects: 0
Study 15189800 — intervention group
Group type: COMPARATOR
Intervention: Chronic fatigue syndrome (CFS)
Number of subjects: 0
Study 15189800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neuroendocrineimmune dysfunction syndrome, which had formerly been called chronic fatigue syndrome
Number of subjects: 0
Study 12764804 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1 * 0101.2 allele
Number of subjects: 35
Study 12764804 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1 * 0302 allele
Number of subjects: 35
Study 12764804 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Total point prevalence of any specific phobia
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of any single specific phobia
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple phobias reported
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal phobia prevalence
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational phobia prevalence
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutilation phobia prevalence
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear ratings for all objects and situations
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Inanimate object fears and phobias
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal fears intensity
Number of subjects: 704
Study 8561762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of flying and fear of injections as a function of age in women
Number of subjects: 704
Study 2045259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest and hospitalisation for women with viable singleton pregnancies of 7-14 weeks gestation and bleeding in the previous 24 hours.
Number of subjects: 23
Study 2045259 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency scanning as a routine part of the gynaecological service.
Number of subjects: 23
Study 2045259 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 23
Study 6337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 gm) at cord clamping
Number of subjects: 189
Study 6337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of Cefoxitin
Number of subjects: 189
Study 6337491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 6337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis
Number of subjects: 189
Study 29278449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production programme
Number of subjects: 0
Study 29278449 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures to overcome water constraints and expand vegetable and poultry production
Number of subjects: 0